Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis.
Eddie A JamesV Michael HolersRadhika IyerE Barton PrideauxNavin L RaoCliff RimsVirginia S MuirSylvia E PossoMichelle S BloomAmin ZiaSerra E ElliottJulia Z AdamskaRizi AiR Camille BrewerJennifer A SeifertLauraKay MossSaman BarzidehM Kristen DemoruelleChristopher C StriebichYuko OkamotoEnkhtsogt SainbayarAlexandra A CrookRyan A PetersonLauren A VanderlindenWei WangDavid L BoyleWilliam H RobinsonJane H BucknerGary S FiresteinKevin D DeanePublished in: Nature communications (2023)
Molecular markers of autoimmunity, such as antibodies to citrullinated protein antigens (ACPA), are detectable prior to inflammatory arthritis (IA) in rheumatoid arthritis (RA) and may define a state that is 'at-risk' for future RA. Here we present a cross-sectional comparative analysis among three groups that include ACPA positive individuals without IA (At-Risk), ACPA negative individuals and individuals with early, ACPA positive clinical RA (Early RA). Differential methylation analysis among the groups identifies non-specific dysregulation in peripheral B, memory and naïve T cells in At-Risk participants, with more specific immunological pathway abnormalities in Early RA. Tetramer studies show increased abundance of T cells recognizing citrullinated (cit) epitopes in At-Risk participants, including expansion of T cells reactive to citrullinated cartilage intermediate layer protein I (cit-CILP); these T cells have Th1, Th17, and T stem cell memory-like phenotypes. Antibody-antigen array analyses show that antibodies targeting cit-clusterin, cit-fibrinogen and cit-histone H4 are elevated in At-Risk and Early RA participants, with the highest levels of antibodies detected in those with Early RA. These findings indicate that an ACPA positive at-risk state is associated with multifaceted immune dysregulation that may represent a potential opportunity for targeted intervention.